ArticleAmerican journal of respiratory and critical care medicine2020
Isoniazid and Rifapentine Treatment Eradicates Persistent
RetractedOpen access · greenAbstract readRetracted Publication
In one paragraph
Article in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Chenodeoxycholic Acid-Amikacin Combination Enhances Eradication of Staphylococcus aureus.Microbiology spectrum · 2023Article
- Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs.The Journal of clinical investigation · 2022Article
- Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis.BMC medicine · 2022Article
- Assay design for unambiguous identification and quantification of circulating pathogen-derived peptide biomarkers.Theranostics · 2022Article
- Retraction: Isoniazid and Rifapentine Treatment Eradicates PersistentAmerican journal of respiratory and critical care medicine · 2021Article
- The immune landscape in tuberculosis reveals populations linked to disease and latency.Cell host & microbe · 2021Article
- One Size Fits All? Not inFrontiers in cellular and infection microbiology · 2021Review
- Treatment of latent M. tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis.The Journal of clinical investigation · 2020Article
- Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model.The Journal of clinical investigation · 2020Article
- Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment.JCI insight · 2020Article
- Modeling Treatment of Latent Tuberculosis: Shortening the Leap of Faith?American journal of respiratory and critical care medicine · 2020Article
Corrections and comments
- Retraction · 2021-04-15Error in Methods · Falsification/Fabrication of Data · Investigation by ORI · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · Unreliable Results and/or Conclusions · · see: https://ori.hhs.gov/content/case-summary-kaushal-deepak
- Commented on by
- Commented on by
- Retracted
Authors and funding
13 authors at 5 institutions in 1 country.
Taylor W ForemanTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana.
Allison N BucşanTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana.
Smriti MehraTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana.
Charles PeloquinUniversity of Florida College of Pharmacy, Gainesville, Florida.
Lara A DoyleTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana.
Kasi Russell-LodrigueTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana.
Neel R GandhiRollins School of Public Health and.
John AltmanEmory Vaccine Center and Yerkes National Primate Center, Emory University, Atlanta, Georgia.
Cheryl L DayEmory Vaccine Center and Yerkes National Primate Center, Emory University, Atlanta, Georgia.
Joel D ErnstDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco, California; and.
Henry M BlumbergDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Jyothi RengarajanEmory Vaccine Center and Yerkes National Primate Center, Emory University, Atlanta, Georgia.ORCID 0000-0003-1241-4705
Deepak KaushalTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana.ORCID 0000-0003-3521-1257
Tulane University · USEmory University · USRollins College · USUniversity of California, San Francisco · USUniversity of Florida · US
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MTulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4MThe Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7MBAA-NIH-NIAID-NCRR-DMID-03-036UC6AI058609 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI LACKNER, ANDREW A · 2003 to 2006
$21.1MRole of antigen-specific T cell responses in the control of TBU19AI111211 · NIAID · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 2014 to 2020
$20.1MImmune Correlates of Protection from TBR01AI134240 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK · 2017 to 2022
$4.8MPerturbation of antigen-specific T cell responses in latent TB/SIV co-infectionR01AI111943 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, RENGARAJAN, JYOTHI · 2015 to 2019
$3.9MImpact of concurrent HIV and latent TB therapies on Mtb-specific immune function-Diversity SupplementR01AI123047 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, RENGARAJAN, JYOTHI · 2017 to 2020
$3.9MMentorship in Patient-Oriented Research in Tuberculosis, HIV and Global HealthK24AI114444 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2014 to 2023
$1.8MNIAID NIH HHS K24 AI114444NIAID NIH HHS R01 AI111943NIAID NIH HHS R01 AI123047NIAID NIH HHS R01 AI134240NIAID NIH HHS U19 AI111211NIAID NIH HHS UC6 AI058609NIH HHS P51 OD011104NIH HHS P51 OD011132NIH HHS P51 OD011133
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntibiotics, AntitubercularAntitubercular AgentsDrug Therapy, CombinationIsoniazidLatent TuberculosisMacacaModels, AnimalMycobacterium tuberculosisRifampinTreatment OutcomeTuberculosisAntibiotics, AntitubercularAntitubercular AgentsIsoniazidRifampinrifapentine3HPisoniazidMycobacterium tuberculosisrifapentine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.